BeOne Medicines: Redefining Cancer Care

Watch on YouTube ↗  |  January 14, 2026 at 15:38  |  11:53  |  Morgan Stanley
Speakers
John V. Oyler — Co-Founder, Chairman and CEO, BeOne Medicines
Sean Laaman — Head of U.S. Mid-Cap Biotech Equity Research, Morgan Stanley

Summary

John V. Oyler, co-founder, chairman and CEO of BeOne Medicines, explains the company's mission to fight cancer through in-house clinical trials, global trial sites, community oncology partnerships, and a focus on affordability and access. He highlights BeOne's cancer-only focus, Brukinsa's approvals, global patient reach, and therapeutic investments in hematology/CLL and solid tumors. The interview also covers company culture and the broader shift of some large pharmaceutical companies away from oncology despite continued patient need.

  • BeOne Medicines was founded in 2010 to fight cancer and improve affordability and access.
  • The company runs clinical trials in-house rather than outsourcing to CROs.
  • It builds global trial sites with community oncologists in Australia, Korea, Brazil, and South Africa.
  • Brukinsa is approved in five indications and more than 60 countries.
  • BeOne has reached over 1.8 million cancer patients and is investing in hematology/CLL and solid tumors.
  • Management says it is increasing oncology investment while some large pharma companies pull back.
  • Oyler emphasizes mission-driven culture and the company's differentiated trial model.
Ideas
John V. Oyler Co-Founder, Chairman and CEO, BeOne Medicines 3:49
Differentiated in-house global oncology model drives growth
BeOne Medicines is pursuing a differentiated oncology strategy: it runs clinical trials in-house instead of outsourcing to CROs, builds a global trial network with community oncologists in countries such as Australia, Korea, Brazil, and South Africa, and uses that infrastructure to cut trial costs and speed development. Management says it remains 90% focused on cancer and is increasing oncology investment even as other large drugmakers pull money out of the field. Brukinsa is already approved in five indications and 60+ countries, has reached over 1.8 million patients, and the company is investing heavily in hematology/CLL and solid tumors including breast, lung, gastrointestinal, and liver cancers.
ONC HIGH
Up Next
1:36
Supreme Court will not issue decision on tariffs today
CNBC · Jan 14
2:09
Existing home sales end 2025 with a strong beat, as prices ease further
CNBC · Jan 14
2:47
Philadelphia Fed President Paulson: Fed funds rate 'still a little restrictive'
CNBC · Jan 14
1:03
Opening Bell: January 14, 2026
CNBC · Jan 14
1:07:35
Mark Blyth: Capitalism Is Crashing Again and Politics Isn’t Ready | Global Macro | Ep.94
Top Traders Unplugged · Jan 14

This Morgan Stanley video, published January 14, 2026, features John V. Oyler discussing ONC. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: John V. Oyler  · Tickers: ONC